Skip to main content

Skin Cancer

Oftentimes, patients with multiple myeloma experience disease progression even after receiving a stem cell transplant. However, according to a recent study, a new long-term therapy, lenalidomide, can be used after transplantation to slow down the progression of the disease.

Read More ›

Continuous use of aspirin for 5 years or more reduces the risk of cutaneous melanoma by almost half, according to results of a case-control study. Continuous use of nonaspirin nonsteroidal anti-inflammatory drugs (NSAIDs) also reduces risk, but only by 25%.

 

Read More ›

Patients with stage IV or locally advanced stage III cutaneous melanoma experienced higher response rates and longer progression-free survival (PFS) when treated with a gp100 vaccine and interleukin-2 than with interleukin-2 alone, in a phase 3 randomized trial. Tumors in all 185 patients expressed HLA*A0201, which allowed presentation of the peptide vaccine to T cells. The researchers concluded that their results show the potential of immune agents in combination with other treatments in this patient population.

 

Read More ›